Exagamglogene autotemcel - Wikipedia
Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy used for the treatment of sickle cell disease [3] [5] and transfusion-dependent beta thalassemia. [3] It was …
CASGEVY® (exagamglogene autotemcel) | Patient Website
CASGEVY is a one-time therapy used to treat people aged 12 years and older with: sickle cell disease (SCD) who have frequent vaso-occlusive crises or VOCs. beta thalassemia (β …
Casgevy: Uses, Dosage, Side Effects, Warnings - Drugs.com
Jan 17, 2024 · Casgevy (exagamglogene autotemcel) is a gene therapy that is given as a one-time intravenous infusion to treat adults and children aged 12 years and older with: Sickle cell …
FDA Approves First Gene Therapies to Treat Patients with Sickle …
Casgevy, a cell-based gene therapy, is approved for the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises. Casgevy is the first...
CASGEVY | FDA - U.S. Food and Drug Administration
CASGEVY indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso occlusive crises (VOCs).
Patient Information | CASGEVY® (exagamglogene autotemcel)
CASGEVY is a one-time* gene therapy that may help people 12 years and older with sickle cell disease (SCD) and frequent vaso-occlusive crises (VOCs) live severe VOC-free. CASGEVY …
HCP Official Website for CASGEVY® (exagamglogene autotemcel)
CASGEVY is indicated for the treatment of patients aged 12 years and older with: sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) transfusion-dependent β …
Casgevy - European Medicines Agency (EMA)
Dec 15, 2023 · Casgevy is a medicine used to treat blood disorders known as beta thalassaemia and sickle cell disease in patients 12 years and older. For beta thalassaemia, Casgevy is used …
Casgevy: Package Insert / Prescribing Information - Drugs.com
Sep 14, 2024 · CASGEVY is an autologous genome edited hematopoietic stem cell-based gene therapy indicated for the treatment of patients aged 12 years and older with: sickle cell disease …
Therapies | CRISPR Therapeutics
CASGEVY™ (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy arising out of our collaboration with Vertex Pharmaceuticals Incorporated, is approved in some countries for …